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Abstract  
  Iron disorder and abnormal expression of hepcidin play important roles in many diseases, but it is still unclear 
in type 2 diabetes mellitus (T2DM).  We aimed to assess iron, ferritin and hepcidin levels in plasma of with or 
without T2DM and evaluated increased body iron stores as risk factor for developing T2DM. Plasma samples 
were collected from 88 participants, who were categorized into 2 groups based on the presence or absence of  
T2DM. Demographics and general health parameters were recorded. Chemiluminescence microparticle 
immunoassay and enzyme-linked immunosorbent assay were used to detect iron, ferritin and hepcidin 
concentrations. The geometric mean±SD of the plasma level of hepcidin, ferritin, iron and insulin among T2DM 
comparing with that of healthy controls were evaluated. Plasma ferritin and hepcidin levels in  T2DM group 
were higher than in the control group (P < 0.05). The geometric mean ± SD of hepcidin and ferritin for T2DM 
were 41.1±23.3 μg/L and 227.2±156.1 ŋg/L respectively;   higher than the 15.2±2.3 μg/L and 114.4± 60.4 ŋg/L 
of  controls respectively. There was a significant associated between high level of plasma hepcidin (OR=2.75) 
and  ferritin (OR = 2.24);  with T2 DM. In conclusion: the regulation of body iron, an essential but also toxic 
element is strictly controlled by a small peptide hormone hepcidin. The present data demonstrated that the higher 
hepcidin level in diabetic patients may be due to those higher ferritin, the elevated hepcidin might have adaptive 
value through down-regulated iron absorb and play an important role in pathogenesis of T2 DM. 
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Introduction      
     Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia caused by impaired insulin 
secretion and/or insulin resistance 
1
.  The role of micronutrients in the etiology of  T2DM is not well established. 
Several lines of evidence suggest that iron play may a role in the pathogenesis of  T2DM
1
.  Iron is an 
indispensable nutrient for the human body; it is essential to maintain systemic iron homeostasis because iron 
disorder in the body can lead to various clinical diseases
2
. Recent facts suggest that increased body iron stores 
play a role in the pathogenesis of T2DM. Yeap et al. 
3
 detected serum ferritin, iron, and transferrin saturation 
among 1834 men and 2351 women and reported that higher serum ferritin levels were independently associated 
with T2DM. In view of the fact that ferritin is generally used as a marker of  body iron stores, this study 
suggested that increased body iron stores is a risk factor for T2DM 
3
. Excessive systemic iron can trigger 
oxidative stress injury in hepatocytes and pancreatic β cells, forming the basis of diabetes, which may cause 
insulin resistance, reduction in insulin secretion, and eventually, development of T2DM 
4,5
. In addition, it has 
been reported that insulin can directly up-regulate hepcidin expression in hepatocellular carcinoma (HepG2) 
cells by enhancing signal transducers and activators of transcription 3 (STAT3) protein synthesis and DNA 
binding activity 
6
, indicating that insulin disorder in T2DM can lead to inadequate hepcidin concentrations. 
Evidence suggests to us that insulin resistance accompanied by insufficient hepcidin levels can progress to overt 
diabetes through more dysfunction of cells via iron overload 
7
. Hepcidin, a key hormone synthesized in the liver, 
can regulate iron homeostasis 
8
; it can prevent iron efflux from macrophages, enterocytes and hepatocytes into 
the plasma by inducing internalization and degradation of the iron exporter ferroportin in these cells 
9
, which 
indicates that the iron overload is further aggravated by inadequate hepcidin in T2DM. Hepcidin expression can 
be regulated by iron-mediated pathways through signaling of JAK/STAT and BMP/SMAD 
10
.  Iron stores can be 
detected using several techniques including liver biopsy 
11
, iron stains on bone marrow trephine biopsy
12
, and 
 serological detection. Serum ferritin level is now widely used in clinical practice and is considered the most 
convenient and cost-effective method to detect iron load 
3
.  Also serum hepcidin has been proved to be an 
indicator of iron load
13
. Moreover, the serum hepcidin/ferritin ratio has been used to evaluate iron metabolism of 
the body as it represents both body iron load and adequacy of hepcidin production for a given iron load
14
.  We 
aimed to assess iron, ferritin and hepcidin levels in serum of with or without T2DM and evaluated increased 
body iron stores as risk factor for developing T2DM Since ferritin is commonly used as a marker of body iron 
stores. 
Subjects and Laboratory Methods 
Subject selection 
After receiving approval from the Ethical Committee, we recruited 46 T2DM patients, and 42 healthy 
individuals; the age of the participants ranged 25–65 years. All participants provided a written informed consent, 
and all steps of the clinical examination and sampling procedures were explained to each participant. 
Participants were diagnosed with T2DM by specialist physicians at the hospital according to the American 
Diabetes Association criteria 
15
. Data regarding demographic and clinical characteristics, including age, body 
mass index (BMI), fasting blood glucose (FBG), triglyceride (TG), cholesterol (CHOL), high-density lipoprotein 
(HDL), low-density lipoprotein (LDL), alanine transaminase (ALT), and aspartate transaminase (AST), were 
recorded in physical examination reports of all participants.  
Collection and storage of  blood  samples 
Blood samples were collected from the antecubital fossa by venipuncture  using a 20-gauge needle with a 5-mL 
syringe. All collections were performed by well-trained nurses at the nursing station. Plasma was separated from 
blood by centrifuging at 3000 rpm for 5 min. Blood samples which occurred hemolysis would be discarded. 
Each plasma  sample was given a tracking number and stored at − 20 °C until further analysis. 
Laboratory Tests 
Ferritin and hepcidin were tested in serum samples using chemiluminescence microparticle immunoassay 
(CMIA) and enzyme-linked immunosorbent assay (ELISA) (Roche, Germany), respectively. The  tests were 
performed according to the manufacturer’s instructions described in the assay procedure. A two-step 
immunoassay was required. Ferritin present in the sample binds to antiferritin-coated microparticles. After 
washing, antiferritin acridinium conjungate was added. Subsequently, Pre-Trigger and Trigger Solutions were 
added to the reaction mixture; the resulting chemiluminescent reaction was measured as relative light units 
(RLUs).  
Data analysis 
   The analysis of data was done by Epi Info version 6 statistical program (CDC, Atlanta, USA), where the chi-
square (χ2) and probability value (p) was calculated for the test of significance by comparing the geometric 
mean ± SD of the plasma level of hepcidin, ferritin, iron and insulin among cases (type 2 DM) comparing with 
that of healthy controls. In addition, Odd's ratio (OR), 95% confidence interval (95% CI) were added to estimate 
the associated OR for high level of hepcidin, ferritin and  iron with T2DM comparing with that of healthy 
controls.  A p value < 0.05 was considered significant.    
 Ethical approval 
We obtained written consent from all cases. Assent was taken from participants before collecting the specimens. 
The study proposal was evaluated and approved by the Ethics Committee of Faculty of Medicine and Health 
Sciences, Sana'a University. 
Result 
   Table 1 summarizes the demographic characteristics of study participants: the mean participant age in the 
T2DM  and control groups was 25.5 ± 2.8, 24.09 ± 2.82 years, respectively. The age of  T2DM patients ranged 
from 30 to 65 years, while for healthy control ranged from 25 to 56 years. The mean participant BMI (kg/m
2
) in 
the T2DM  and control groups was 50.05 ± 9.54 and 33.63 ± 9.75  kg/m2 respectively.  Fasting blood glucose 
levels were significantly higher in patients with T2DM than in those without T2DM (P < 0.05). However, no 
significant intergroup differences were noted in terms of sex, CHOL, HDL and LDL (P > 0.05) (table 1). Table 2 
shows the geometric mean ± SD of the plasma level of hepcidin, ferritin, iron and insulin among T2DM 
comparing with that of healthy controls. The geometric mean± SD of hepcidin μg/L for DM patients were 
41.1±23.3 μg/L higher than the 15.2 ± 2.3 μg/L of healthy controls. In addition the hepcidin level for T2DM 
patients was ranged from 17.2 μg/L to 76.6 μg/L while for healthy controls was ranged from10.2 μg/L to 19 
μg/L only much lower than that of the T2 DM patients. The geometric mean±SD of ferritin ŋg/L for T2DM were 
227.2 ± 156.1 ŋg/L higher than the 114.4± 60.4 ŋg/L of healthy controls. In addition the ferritin level for T2DM 
was ranged from 30.3 ŋg/L to 638.3 ŋg/L while for healthy controls was ranged from 20.2 ŋg/L to 258 ŋg/L 
lower than that of the T2DM. The geometric mean± SD of iron μg/dL for T2DM patients were 89.2± 34.4μg/L 
slightly higher than the 82.1± 23.8 μg/dL of healthy controls. In addition the iron level for T2DM was ranged 
from 17.3 μg/dL to 158 μg/dL and for healthy controls was ranged from 24.3 μg/dL to 132 μg/dL slightly lower 
than that of the T2DM.  The geometric mean±SD of insulin μU/ml for T2DM were 8.5±6 μU/ml is roughly 
similar to the 8.6±3.1 μU/ml of healthy controls. In addition the insulin level for T2DM was ranged from 2 
μU/ml to 32.1μU/ml and for healthy controls was ranged from 3.4 μU/ml to 17.1 μU/ml slightly lower than that 
of the T2DM. Table 3 shows the associated odds ratio of high levels of  iron, hepcidin, ferritin, and insulin in T2 
DM comparing with healthy controls. There was a significant associated Odds ratio between high level of 
plasma iron and type 2 DM in which the associated OR is equal to 1.98 times, with 95% CI=1.6-24, χ2=3.9 and 
p=0.05.  Also, there was a significant associated Odds ratio between high level of plasma hepcidin and type 2 
DM in which the associated OR= 2.75 with 95% CI= 2 – 3.8, χ2 = 26.7 and p<0.001. Additionally, there was a 
significant associated Odds ratio between high level of plasma ferritin and T2DM in which the associated 
OR=2.24, 95%CI=1.74 – 2.9, χ2=12.7 and p<0.001.  As well,  there was a non-significant associated Odds ratio 
between high level of plasma insulin and type 2 DM (OR=3.9, p=0.2).  
 Discussion 
     Diabetes Mellitus is a predominant public health concern, affecting millions of people worldwide.  The 
disease causes substantial morbidity and mortality and long term complications. In the last 15 years, it is 
recognized that, increased body iron stores are associated with the development of Glucose intolerance, 
gestational diabetes and Type-2 diabetes 
16
. The aim of our study was to confirm the association of increased 
plasma iron, hepcidin, and ferritin level with the development of glucose intolerance and Type-2 diabetes 
comparing with plasma iron, hepcidin, and ferritin level of healthy controls.  
     In our study there was a significant association between high level of serum iron concentration (>150 µg/dl)  
with DM by means of associated odds ratio equal to 1.98, comparing with healthy controls (p=0.05). This result 
is similar to that reported by Wrede et al.
17
 and Cavallo et al 
18
 in which increased serum iron negatively 
correlate with insulin sensitivity and the presence of insulin resistance syndrome.  This negative correlation can 
 be explained by the significant tissue accumulations of iron can lead to pathology in the liver, heart, endocrine 
organs, and musculoskeletal system 
14
.  Excess iron deposition in the pancreas is known to cause a secondary 
form of diabetes, which has lead to speculation that higher concentrations of iron may increase the risk of 
developing diabetes. Earlier studies provided mixed evidence in support of the iron–diabetes hypothesis, and 
consequently the hypothesis was largely dismissed 
19
. The existence of an iron regulatory hormone was 
postulated primarily to account for the observed interactions between the anatomically distinct sites of iron 
absorption, recycling and utilization. 
    Hepcidin is now acknowledged to be the main iron regulatory hormone. It is a 25-amino acid peptide 
exclusively synthesized by the liver, initially identified as part of a search for novel antimicrobial peptides
20,21
. 
There was no indication that it had an additional role in iron metabolism until 2001, when mouse studies were 
published showing that hepatic hepcidin mRNA synthesis was induced by iron loading  
22,23
.  In our study there 
was a highly significant association between high level of serum hepcidin concentration (>75 µg/dl)  with T2DM 
by means of associated odds ratio equal to 2.75 (95% CI=2 – 3.78) times comparing with healthy controls, with 
χ2 equal to 26.7, and p value less than 0.001 (table 3). This result is similar to that reported by Darshan and 
Anderson 
2
 in which increased serum hepcidin is correlated with DM type 2 and insulin resistance DM cases.  
     The association Hepcidin with DM and iron concentration can be explained by that  the rate of iron efflux 
into the plasma depends primarily on the plasma level of hepcidin; when iron levels are high the synthesis of 
hepcidin increases and the release of iron from enterocytes and macrophages are diminished. Conversely when 
iron stores drop, the synthesis of hepcidin is down-regulated and these cells release more iron
24,25
. 
      What's more, in our study there was a significant association between high level of serum ferritin  
concentration (>600  ŋg /dl)  with T2DM by means of associated odd's ratio equal to 2.24(p< 0.001) comparing 
with healthy controls. This result is similar to that reported by Redmon et al. 
26
, and Fleming
27
 in which 
increased serum ferritin is correlated with DM type 2 and insulin resistance DM cases. 
     Serum ferritin (SF) has been reported to negatively correlate with insulin sensitivity 
18
 and the presence of 
insulin resistance syndrome
 28,29
.  Furthermore insulin resistance, compensated by Hyperinsulinaemia, sets in 
early even before the onset of frank diabetes mellitus and correlate well with indicators of iron overload and 
SF
28
. Additionally  other evidence clear the effect of ferritin on iron overload and the encouraging the  
development of  DM type 2 is that frequent blood donation lead to decrease iron stores, which in turn reduces 
post-prandal Hyperinsulinaemia in healthy volunteers and improves insulin sensitivity
23
. Insulin resistance, 
correlate well with total units of  blood transfused, splenomegaly and SF in chronically transfused patients of 
thalassemia major 
28
. Also, phlebotomy is followed by drop in serum glucose, serum Cholesterol, serum 
triglycerides and improvement in both beta cell secretion and peripheral insulin action in type-2 diabetes 
mellitus
30
.  As well epidemiological studies suggest that high body iron stores are associated with insulin 
resistance and type 2 diabetes with high level of serum ferritin
31,32
. Also our result is suggested that 26.1% (table 
3) of our T2DM patients (might developed IRS (Insulin Resistance Syndrome) this suggestion supported by   
Wrede et al 
17
 which reported a significant correlation between SF and the presence of IRS criteria in a large 
representative population.  
     Fernandez-Real et al.
33
 found that in general population increased body iron stores are possibly associated 
with occurrence of glucose intolerance, type-2 diabetes and gestational diabetes. Facchini, 
29
 found significant 
reduction in serum insulin concentration after performing a 550 ml phlebotomy in healthy volunteers. 
Bloodletting of 1500 ml has been demonstrated to improve insulin sensitivity and to decrease C-peptide 
secretion in type -2 diabetes subjects who had decreased SF concentration. Similarly Dmochowski et al 
34
 and 
Jehn et al. 
35
 reported in a study on thalassemic patients that SF concentration correlated negatively with insulin 
sensitivity and the conclusion of the study showed a major and significant insulin resistance which may be 
compensated for by an elevated circulating insulin level. Dymock et al 
36
 and Swaminathan et al 
37
 reported 
 significant reduction in total daily insulin dosage following phlebotomy and improvement in diabetic status of 
patients following venesection. Further epidemiological studies also support these findings which suggest that 
high body iron stores are associated with insulin resistance and type 2 diabetes
38, 39
. 
      In conclusion our study examined the association between ferritin concentration and diabetes, and  we found 
that serum ferritin concentration was strongly associated with newly diagnosed diabetes.  Because these results 
are based on cases control  data, any causal inference is speculative. These results support similar findings from 
other studies
31,40
. In our study high level ferritin found in 26.1% of our DM similar to some studies, high ferritin 
concentrations were found in 6–33% of patients with type 2 diabetes, which suggests that ferritin concentration 
may be abnormally high among individuals with diabetes 
31,40
. Several studies have produced mixed findings 
about differences in ferritin concentration between diabetic patients and control subjects
41, 42, 43
. One study 
suggested that treating diabetic patients with desferoxamine lowered ferritin concentrations and improved the 
management of diabetes
44
, but these findings were not confirmed in others studies
19,45
. At least three possible 
explanations may account for the elevated ferritin concentrations in participants with diabetes:  First, elevated 
ferritin concentrations may represent elevated iron body stores. Second, ferritin is also an acute-phase reactant, 
and elevated ferritin concentrations may reflect inflammation. Third, delayed clearance of glycosylated ferritin in 
participants with diabetes may have led to elevated ferritin concentrations
40,43,46
. 
     The synthesis of  hepcidin is also enhanced by an increased body iron stores
47
. Hepcidin levels were 
increased significantly in all diabetic patients compared with normal control in our research, and a significant 
positive correlation between hepcidin and ferritin which was marked in diabetic group (tables 2,3). The 
regulation of hepcidin by body iron acts as a feedback mechanism to allow sufficient iron to enter the plasma 
when the demand for iron is high, but to limit iron release into the plasma in times of iron sufficiency. Then, 
hepcidin acts as a negative regulator of intestinal iron absorption and macrophage iron release. Our data 
demonstrated that the elevated hepcidin in Type 2 DM patients may be due to those elevated ferritin levels, and 
this confirmed with study of Fang Jiang, et al.
48
. The confirmation of an increased risk of diabetes with 
moderately elevated ferritin levels could have clinical and public health consequences, since persons at high risk 
could be targeted for more intensive screening and preventive interventions 
39
. From these points, the elevated 
hepcidin concentrations may have adaptive value through down-regulated iron absorb in patients with Type 2 
DM. Hepcidin concentration may be useful to predict which patients could benefit from it although the potential 
use of hepcidin targeted therapeutics are yet available
48
. 
 
Conclusion 
     The geometric mean + SD of the plasma level of hepcidin, ferritin, iron and insulin among cases (type 2 DM) 
were higher than that of healthy controls. The regulation of body iron, an essential but also toxic element is 
strictly controlled by a small peptide hormone hepcidin. The present data demonstrated that the higher hepcidin 
level in diabetic patients may be due to those higher ferritin, the elevated hepcidin might have adaptive value 
through down-regulated iron absorb and play an important role in pathogenesis of type 2 DM. 
 
Recommendation 
     A wider knowledge of hepcidin regulation will provide us with novel tools for differential diagnosis, 
therapeutic regimes and monitoring of disorders of iron metabolism.  However, a lot remains to be uncovered on 
the biology and function of hepcidin. Its signaling pathways are as yet to be delineated. Further studies are 
needed to define precisely the hepcidin role in iron metabolism homeostasis and its utility in the diagnosis and 
treatment of iron disorders. Also that more studies need to be performed regarding the role of ferritin in pre-
diabetic stage as well as in type 2 diabetics. Finally prospective studies are needed to confirm whether elevated 
 serum ferritin predicts insulin resistance and its associated conditions, or is merely a secondary marker of 
metabolic abnormalities. 
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    Table 1 : The comparison of parameters between type 2 DM and control groups. 
 
Biochemical 
parameters 
Type 2 DM n= 46 Healthy control n= 42 
P. value 
Geometric mean + 
SD 
Min – Max 
Geometric mean + 
SD 
Min – Max 
BMI kg/m
2
 
50.05 + 9.54 - 33.63 + 9.75 - 0.001 
Age 
25.45 + 2.8 30 – 65 years 24.91 + 2.82 30 - 56 0.908 
FBS mg/dl 
219.8 + 73.8 128 – 400 95.2 + 7 82 – 108 0.001 
HDL mmol/L 1.06 + 0.32 0.5 – 2.5 1.06 + 0.2 0.7 – 1.7 0.908 
LDL mmol/L 3.1 + 0.81 1.7 – 5.2 2.91 + 0.8 1.3 – 4.6 0.394 
Triglycerides mmol/L 2.3 + 1.7 0.7 – 11.9 1.5 + 0.5 0.6 – 2.6 0.002 
T. cholesterol 
mmol/L 
5.4 + 1.1 3.8 – 8.4 4.97 + 0.99 2.6 – 6.9 0.054 
 
    
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: The plasma level of hepcidin, ferritin, iron and insulin among cases (type 2 DM) and healthy controls. 
 
Biochemical 
parameters 
Type 2 DM n= 46 Healthy control n= 42 
P. value Geometric mean + 
SD 
Min - Max 
Geometric mean + 
SD 
Min - Max 
Hepcidin µg/L 41.1 + 23.3 17.2 – 76.9 15.2 + 2.3 10.2 – 19 <0.001 
Ferritin ŋg/L 227.2 + 156.1 30.3 – 638.3 114.4 + 60.4 20.2 – 258 <0.001 
Iron µg/dl 89.2 + 34.4 17.3 – 158 82.1 + 23.8 24.3 – 132 0.15 
Insulin µU/ml 8.5 + 6 2 – 32.1 8.6 + 3.1 3.4 – 17.1 0.80 
 
 
  Table 3 : The associated odds ratio of high iron, hepcidin, ferritin, insulin, in type 2 DM comparing with 
healthy controls. 
Biochemical 
parameters 
High level DM 
High level 
control OR CI χ2 P 
No % No % 
Iron µg/dl 3 6.5 0 0 1.98 1.6-24 3.9 0.05 
Hepcidin µg/L 22 48 0 0 2.75 2-3.8 26.7 <0.001 
Ferritin ŋg/L 12 26.1 0 0 2.24 1.74-2.9 12.7 <0.001 
Insulin µU/ml 4 8.7 1 2.4 3.9 0.4-95.8 1.63 0.2 
 
OR          Odds ratio = Relative risk  
CI           Confidence intervals  
 χ 2          Chi-square = 3.9  or more significant 
 pv           Probability value = 0.05 or less  significant 
      
